The ALPHA3 Trial: Next-Gen CAR T and MRD Testing in LBCL

Abstract

Get full access to this article

View all access options for this article.

References

Crump

, Neelapu

, Farooq

, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800–1808. doi:10.1182/blood-2017-03-769620

Roschewski

, Kurtz

, Westin

, et al. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. Published online August 13, 2025. doi:10.1200/JCO-25-01534

www.nccn.org

Locke

, Miklos

, Jacobson

, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. , 2022; 386(7):640–654. doi:10.1056/NEJMoa2116133